Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions

具有不同表位特异性和Fc效应功能的交叉反应性冠状病毒抗体

阅读:3
作者:Andrea R Shiakolas,Kevin J Kramer,Daniel Wrapp,Simone I Richardson,Alexandra Schäfer,Steven Wall,Nianshuang Wang,Katarzyna Janowska,Kelsey A Pilewski,Rohit Venkat,Robert Parks,Nelia P Manamela,Nagarajan Raju,Emilee Friedman Fechter,Clinton M Holt,Naveenchandra Suryadevara,Rita E Chen,David R Martinez,Rachel S Nargi,Rachel E Sutton,Julie E Ledgerwood,Barney S Graham,Michael S Diamond ,Barton F Haynes,Priyamvada Acharya,Robert H Carnahan,James E Crowe Jr ,Ralph S Baric,Lynn Morris,Jason S McLellan,Ivelin S Georgiev

Abstract

The continual emergence of novel coronaviruses (CoV), such as severe acute respiratory syndrome-(SARS)-CoV-2, highlights the critical need for broadly reactive therapeutics and vaccines against this family of viruses. From a recovered SARS-CoV donor sample, we identify and characterize a panel of six monoclonal antibodies that cross-react with CoV spike (S) proteins from the highly pathogenic SARS-CoV and SARS-CoV-2, and demonstrate a spectrum of reactivity against other CoVs. Epitope mapping reveals that these antibodies recognize multiple epitopes on SARS-CoV-2 S, including the receptor-binding domain, the N-terminal domain, and the S2 subunit. Functional characterization demonstrates that the antibodies mediate phagocytosis-and in some cases trogocytosis-but not neutralization in vitro. When tested in vivo in murine models, two of the antibodies demonstrate a reduction in hemorrhagic pathology in the lungs. The identification of cross-reactive epitopes recognized by functional antibodies expands the repertoire of targets for pan-coronavirus vaccine design strategies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。